Search PubMed⌕ Search

Biomedical subjects

C Itoh

Publications and source records attributed to C Itoh.

At least 73 records · Page 4Linked to original sources
PubMed1990

[New techniques of immunochemical analysis: clinical application of time-resolved fluoroimmunoassay to CA 50 determination].

New techniques in immunochemical analysis were reviewed briefly. Introduction of these new techniques into routine tests has made test results more precise and informative than before. By using one of these techniques, time-resolved fluoroimmunoassay, serum concentrations of CA 50 were quantitated in various malignancies. Clinical usefulness of its quantitation was proved especially in the diagnosis of pancreatic cancer.

Adolescent↗
PubMed1989

The ventromedial nucleus of the hypothalamus outputs long-lasting running in rats.

We have developed a new technique for altering neural construction by implanting self-swelling, the hydrogel of water-absorbent polymer (WAPGEL) into restricted areas of the brain. Using this technique, we found that the VMH is responsible for expression of running activity. Implantation of 1.5 microliters of WAPGEL into the dorsomedial portion of the ventromedial nucleus of the hypothalamus (VMH) of the rat specifically induced bursts of running, whereas implantation into other sites of hypothalamus, e.g., the anterior, lateral and posterior areas, and the dorsomedial nucleus, caused no significant running activity. The WAPGEL-injected rat showed less aversive reactions than the sham-operated rat. Since deafferentation of the VMH after WAPGEL injection prevented the induction of running activity, the output from the VMH appeared to be responsible for the running activity.

Animals↗
PubMed1989

[Preventive medicine of adult T-cell leukaemia].

Preventive medicine of adult T cell leukemia (ATL) was discussed from four points of view, namely (1) seroepidemiology, (2) clinical laboratory findings of HTLV-I seropositive and seronegative groups in comparison with those of ATL patients, (3) relationship between genetic polymorphisms of 4 serum proteins and HTLV-I infection/development of ATL and (4) detection of antibodies to HTLV-I in pregnant women and prevention of its mother to child transmission.

Adult↗
PubMed1988

Adult T-cell leukemia by probable horizontal transmission from husband to wife.

A 60-year-old housewife was affected with adult T-cell leukemia (ATL) 10 years after her husband died of T-cell lymphoma, which was retrospectively diagnosed as ATL. She had never had a blood transfusion nor any indication of infection by human T-cell lymphotropic virus type I (HTLV-I) from her parents. The report suggested the wife to have developed ATL by horizontal transmission of HTLV-I from her husband 31 years after their marriage.

Deltaretrovirus Infections↗
PubMed1986

[A double-blind comparative study on the efficacy of S6472, cefaclor, in the treatment of bacterial bronchitis].

Clinical efficacy and safety of S6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375 mg of S6472 2 times or 250 mg of CCL 3 times daily for 7 days, and the following results were obtained. Clinical efficacy judged by a committee: The efficacy rates on acute bronchitis were 87.2% for S6472 and 82.6% for CCL, and the efficacy rates on chronic bronchitis were 70.3% for S 6472 and 64.7% for CCL. There was no significant difference between the 2 drugs in clinical efficacy. Clinical efficacy judged by doctors in charge: Results of the clinical efficacy judged by doctors in charge were similar to the efficacy judged by the committee. Bacteriological efficacy judged by the committee: Eradication rate for the S6472 group was 71.1% (32 of 45 patients) and that for the CCL group was 67.4% (29 of 43 patients). There was no significant difference between the 2 drugs in the bacteriological efficacy. Side effects and abnormal laboratory findings: Side effects were observed in 5 cases (4.2%) in the S6472 group and in 5 cases (4.0%) in the CCL group. These side effects, however, were not serious, and no remarkable abnormal laboratory values were observed. There was no significant difference between the 2 drugs in the incidence of side effects or abnormal laboratory findings. Clinical utility: When the clinical utility was expressed by the utility rate (very useful and useful), it was 79.5% in the S6472 group (117 patients) and 76.2% in the CCL group (122 patients) (judged by the committee). When the utility was judged by doctors in charge, it was 73.3% in S6472 group (120 patients) and 71.4% in CCL group (126 patients). From the above results, it has been concluded that S6472 taken twice daily is equivalent to CCL in effectiveness on bacterial bronchitis.

Adult↗